Skip to main content
main-content

Spondyloarthropathies

Highlights

20-12-2018 | Rheumatoid arthritis | Highlight | News

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

Source:

Arthritis Res Ther 2018; doi:10.1186/s13075-018-1764-z

19-12-2018 | Diagnosis and screening | Podcast | Audio

The importance of early diagnosis and treatment of inflammatory arthritis

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

18-12-2018 | Psoriatic arthritis | Feature | Article

Recognizing and managing cardiovascular risk in PsA patients

medwireNews speaks to Lihi Eder about why patients with psoriatic arthritis have elevated cardiovascular risk, and what can be done to mitigate it.

10-12-2018 | Psoriatic arthritis | Highlight | News

ACR/NPF guidelines for the treatment of PsA published

The American College of Rheumatology and the National Psoriasis Foundation have issued evidence-based guidelines for the pharmacologic and nonpharmacologic treatment of active psoriatic arthritis.

Source:

Arthritis Rheumatol 2018; doi:10.1002/art.40726
Arthritis Care Res 2018; doi:10.1002/acr.23789
J Psoriasis Psoriatic Arthritis 2018; doi:10.1177/2475530318812244

15-11-2018 | Etanercept biosimilar | Highlight | News

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213474

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

Author:
Eoin Feeney

13-11-2018 | Ankylosing spondylitis | Highlight | News

Golimumab may reduce uveitis risk in patients with ankylosing spondylitis

Findings from the real-world GO-EASY study suggest that treatment with the tumor necrosis factor inhibitor golimumab is associated with a significant reduction in the risk for acute anterior uveitis among patients with ankylosing spondylitis.

Source:

J Rheumatol 2018; doi:10.3899/jrheum.180312

24-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | News

Etanercept outperforms methotrexate for PsA

Etanercept has greater efficacy than methotrexate for the treatment of psoriatic arthritis, suggest phase III trial results presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

Source:

ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

23-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | News

Filgotinib shows promise in psoriatic arthritis treatment

The selective janus kinase 1 inhibitor filgotinib has shown efficacy in patients with psoriatic arthritis with no new safety signals, show phase II data from the EQUATOR study.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)32483-8
ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

23-10-2018 | Ankylosing spondylitis | ACR/ARHP 2018 | News

COAST-V results support ixekizumab for the treatment of ankylosing spondylitis

Phase III trial results indicate that ixekizumab may be a promising treatment option for biologic-naïve patients with ankylosing spondylitis and an inadequate response or intolerance to nonsteroidal anti-inflammatory drugs.

Source:

Lancet 2018; doi:10.1016/S0140-6736(18)31946-9
Lancet 2018; doi:10.1016/S0140-6736(18)32340-7
ACR/ARHP Annual Meeting; Chicago, Illinois, USA: 19–24 October 2018

18-10-2018 | Microbiome | Editorial | Article

Why every rheumatologist should understand the microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

Authors:
James T Rosenbaum, Mark J Asquith

10-10-2018 | Mental health | Editorial | Article

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

Author:
Susan Bartlett

07-09-2018 | Treatment | Feature | Article

At a glance: Common scores used in rheumatology

A quick-reference guide to the scores that are commonly used in clinical trials and daily rheumatology practice.

20-08-2018 | Psoriatic arthritis | Feature | Article

At a glance: Data supporting the approval of ixekizumab for PsA

A quick-reference guide to the clinical trial data supporting the approval of ixekizumab for the treatment of psoriatic arthritis.

20-08-2018 | Psoriatic arthritis | Feature | Article

Into the clinic: Ixekizumab for the treatment of PsA

medwireNews summarizes the key data supporting the approval of ixekizumab for the treatment of psoriatic arthritis, and discusses its place in the treatment landscape with Philip Mease and Laura Coates.

26-07-2018 | Psoriatic arthritis | Article

Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA

Merola JF, Herrera V, Palmer JB. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4187-y

11-07-2018 | Arthroplasty | Review | Article

Total joint arthroplasty in patients with inflammatory rheumatic diseases

Compagnoni R, Gualtierotti R, Randelli P. Adv Ther 2018. doi: 10.1007/s12325-018-0750-9

20-07-2018 | Physical activity | Highlight | News

Physical activity recommendations for patients with OA and inflammatory arthritis published

EULAR has issued evidence-based recommendations for physical activity in patients with osteoarthritis and inflammatory arthritis.

Source:

Ann Rheum Dis 2018; doi:10.1136/annrheumdis-2018-213585

image credits